BRAF and metastatic melanoma: To date, the detection of the BRAF-V600E mutation by a certified assay is required in order for stage IV metastatic melanoma patients to be prescribed targeted therapy treatment with dabrafenib and trametinib (FDA approval, 2014), vemurafenib and cobimetinib (FDA approval, 2015), or encorafenib and binimetinib (FDA approval, 2018).